Packaged Foods
Compare Stocks
4 / 10Stock Comparison
HCWC vs OPRX vs DOCS vs GDRX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
Medical - Healthcare Information Services
Medical - Healthcare Information Services
HCWC vs OPRX vs DOCS vs GDRX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Packaged Foods | Medical - Healthcare Information Services | Medical - Healthcare Information Services | Medical - Healthcare Information Services |
| Market Cap | $4M | $124M | $5.24B | $973M |
| Revenue (TTM) | $78M | $109M | $638M | $788M |
| Net Income (TTM) | $-4M | $5M | $239M | $29M |
| Gross Margin | 39.6% | 67.3% | 89.7% | 81.0% |
| Operating Margin | -1.5% | 10.7% | 37.4% | 12.4% |
| Forward P/E | — | 7.0x | 16.8x | 9.0x |
| Total Debt | $26M | $5M | $12M | $60M |
| Cash & Equiv. | $2M | $23M | $210M | $262M |
HCWC vs OPRX vs DOCS vs GDRX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| Healthy Choice Well… (HCWC) | 100 | 11.4 | -88.6% |
| OptimizeRx Corporat… (OPRX) | 100 | 85.9 | -14.1% |
| Doximity, Inc. (DOCS) | 100 | 59.7 | -40.3% |
| GoodRx Holdings, In… (GDRX) | 100 | 40.9 | -59.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HCWC vs OPRX vs DOCS vs GDRX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HCWC is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 24.6%, EPS growth 55.6%, 3Y rev CAGR 83.5%
- 24.6% revenue growth vs GDRX's 0.6%
- -24.8% vs DOCS's -55.4%
OPRX is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 2.28
- 110.5% 10Y total return vs DOCS's -50.9%
- Lower P/E (7.0x vs 16.8x)
DOCS carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 1.03, Low D/E 1.1%, current ratio 6.97x
- Beta 1.03, current ratio 6.97x
- 37.5% margin vs HCWC's -5.4%
- Beta 1.03 vs OPRX's 2.28, lower leverage
GDRX lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 24.6% revenue growth vs GDRX's 0.6% | |
| Value | Lower P/E (7.0x vs 16.8x) | |
| Quality / Margins | 37.5% margin vs HCWC's -5.4% | |
| Stability / Safety | Beta 1.03 vs OPRX's 2.28, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | -24.8% vs DOCS's -55.4% | |
| Efficiency (ROA) | 20.7% ROA vs HCWC's -11.7%, ROIC 20.0% vs -5.6% |
HCWC vs OPRX vs DOCS vs GDRX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
HCWC vs OPRX vs DOCS vs GDRX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DOCS leads in 3 of 6 categories
HCWC leads 0 • OPRX leads 0 • GDRX leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GDRX is the larger business by revenue, generating $788M annually — 10.1x HCWC's $78M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to HCWC's -5.4%. On growth, HCWC holds the edge at +29.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $78M | $109M | $638M | $788M |
| EBITDAEarnings before interest/tax | $2M | $16M | $250M | $184M |
| Net IncomeAfter-tax profit | -$4M | $5M | $239M | $29M |
| Free Cash FlowCash after capex | $2M | $12M | $314M | $132M |
| Gross MarginGross profit ÷ Revenue | +39.6% | +67.3% | +89.7% | +81.0% |
| Operating MarginEBIT ÷ Revenue | -1.5% | +10.7% | +37.4% | +12.4% |
| Net MarginNet income ÷ Revenue | -5.4% | +4.7% | +37.5% | +3.7% |
| FCF MarginFCF ÷ Revenue | +2.2% | +10.6% | +49.2% | +16.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.5% | -0.2% | +9.8% | -4.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +56.0% | — | -16.2% | -1.3% |
Valuation Metrics
Evenly matched — HCWC and OPRX and GDRX each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 23.5x trailing earnings, DOCS trades at a 30% valuation discount to GDRX's 33.3x P/E. On an enterprise value basis, GDRX's 4.0x EV/EBITDA is more attractive than DOCS's 21.1x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $4M | $124M | $5.2B | $973M |
| Enterprise ValueMkt cap + debt − cash | $27M | $105M | $5.0B | $771M |
| Trailing P/EPrice ÷ TTM EPS | -0.59x | 24.56x | 23.45x | 33.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 7.04x | 16.83x | 8.98x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.30x | — |
| EV / EBITDAEnterprise value multiple | — | 6.55x | 21.14x | 4.01x |
| Price / SalesMarket cap ÷ Revenue | 0.05x | 1.13x | 9.18x | 1.22x |
| Price / BookPrice ÷ Book value/share | 1.13x | 0.98x | 4.84x | 1.65x |
| Price / FCFMarket cap ÷ FCF | — | 6.62x | 19.64x | 5.92x |
Profitability & Efficiency
DOCS leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
DOCS delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-74 for HCWC. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to HCWC's 10.72x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs HCWC's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -73.9% | +4.2% | +24.4% | +4.8% |
| ROA (TTM)Return on assets | -11.7% | +3.0% | +20.7% | +1.9% |
| ROICReturn on invested capital | -5.6% | +7.1% | +20.0% | +13.0% |
| ROCEReturn on capital employed | -8.5% | +7.6% | +22.3% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 8 | 9 | 6 |
| Debt / EquityFinancial leverage | 10.72x | 0.04x | 0.01x | 0.10x |
| Net DebtTotal debt minus cash | $23M | -$19M | -$197M | -$202M |
| Cash & Equiv.Liquid assets | $2M | $23M | $210M | $262M |
| Total DebtShort + long-term debt | $26M | $5M | $12M | $60M |
| Interest CoverageEBIT ÷ Interest expense | -1.15x | 1.26x | — | 3.61x |
Total Returns (Dividends Reinvested)
DOCS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DOCS five years ago would be worth $4,911 today (with dividends reinvested), compared to $544 for HCWC. Over the past 12 months, HCWC leads with a -24.8% total return vs DOCS's -55.4%. The 3-year compound annual growth rate (CAGR) favors DOCS at -8.8% vs HCWC's -62.1% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +1.5% | -46.6% | -39.9% | +3.3% |
| 1-Year ReturnPast 12 months | -24.8% | -30.1% | -55.4% | -25.1% |
| 3-Year ReturnCumulative with dividends | -94.6% | -54.4% | -24.2% | -38.4% |
| 5-Year ReturnCumulative with dividends | -94.6% | -87.3% | -50.9% | -91.8% |
| 10-Year ReturnCumulative with dividends | -94.6% | +110.5% | -50.9% | -94.4% |
| CAGR (3Y)Annualised 3-year return | -62.1% | -23.0% | -8.8% | -14.9% |
Risk & Volatility
Evenly matched — DOCS and GDRX each lead in 1 of 2 comparable metrics.
Risk & Volatility
DOCS is the less volatile stock with a 1.03 beta — it tends to amplify market swings less than OPRX's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GDRX currently trades 48.9% from its 52-week high vs HCWC's 29.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.66x | 2.28x | 1.03x | 1.58x |
| 52-Week HighHighest price in past year | $0.98 | $22.25 | $76.51 | $5.81 |
| 52-Week LowLowest price in past year | $0.22 | $5.54 | $20.55 | $1.77 |
| % of 52W HighCurrent price vs 52-week peak | +29.1% | +29.8% | +34.0% | +48.9% |
| RSI (14)Momentum oscillator 0–100 | 56.8 | 46.9 | 60.1 | 66.1 |
| Avg Volume (50D)Average daily shares traded | 500K | 476K | 2.7M | 2.3M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: OPRX as "Buy", DOCS as "Buy", GDRX as "Hold". Consensus price targets imply 156.4% upside for OPRX (target: $17) vs 12.3% for GDRX (target: $3).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $17.00 | $42.79 | $3.19 |
| # AnalystsCovering analysts | — | 15 | 22 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +2.3% | +21.3% |
DOCS leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
HCWC vs OPRX vs DOCS vs GDRX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is HCWC or OPRX or DOCS or GDRX a better buy right now?
For growth investors, Healthy Choice Wellness Corp.
(HCWC) is the stronger pick with 24. 6% revenue growth year-over-year, versus 0. 6% for GoodRx Holdings, Inc. (GDRX). Doximity, Inc. (DOCS) offers the better valuation at 23. 5x trailing P/E (16. 8x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HCWC or OPRX or DOCS or GDRX?
On trailing P/E, Doximity, Inc.
(DOCS) is the cheapest at 23. 5x versus GoodRx Holdings, Inc. at 33. 3x. On forward P/E, OptimizeRx Corporation is actually cheaper at 7. 0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — HCWC or OPRX or DOCS or GDRX?
Over the past 5 years, Doximity, Inc.
(DOCS) delivered a total return of -50. 9%, compared to -94. 6% for Healthy Choice Wellness Corp. (HCWC). Over 10 years, the gap is even starker: OPRX returned +110. 5% versus HCWC's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HCWC or OPRX or DOCS or GDRX?
By beta (market sensitivity over 5 years), Doximity, Inc.
(DOCS) is the lower-risk stock at 1. 03β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately 122% more volatile than DOCS relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 11% for Healthy Choice Wellness Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — HCWC or OPRX or DOCS or GDRX?
By revenue growth (latest reported year), Healthy Choice Wellness Corp.
(HCWC) is pulling ahead at 24. 6% versus 0. 6% for GoodRx Holdings, Inc. (GDRX). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to 54. 2% for Doximity, Inc.. Over a 3-year CAGR, HCWC leads at 83. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HCWC or OPRX or DOCS or GDRX?
Doximity, Inc.
(DOCS) is the more profitable company, earning 39. 1% net margin versus -6. 5% for Healthy Choice Wellness Corp. — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -2. 6% for HCWC. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HCWC or OPRX or DOCS or GDRX more undervalued right now?
On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 7.
0x forward P/E versus 16. 8x for Doximity, Inc. — 9. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.
08Which pays a better dividend — HCWC or OPRX or DOCS or GDRX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is HCWC or OPRX or DOCS or GDRX better for a retirement portfolio?
For long-horizon retirement investors, Doximity, Inc.
(DOCS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03)). OptimizeRx Corporation (OPRX) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DOCS: -50. 9%, OPRX: +110. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HCWC and OPRX and DOCS and GDRX?
These companies operate in different sectors (HCWC (Consumer Defensive) and OPRX (Healthcare) and DOCS (Healthcare) and GDRX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: HCWC is a small-cap high-growth stock; OPRX is a small-cap high-growth stock; DOCS is a small-cap high-growth stock; GDRX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.